Review Article | Published:

2017 Emily Couric Memorial Lecture: Colorectal Cancer: Polyps, Prevention, and Progress

The American Journal of Gastroenterology (2018) | Download Citation

Subjects

Abstract

Colorectal cancer remains the second-leading cause of cancer death in the United States—but efforts over the past two decades have resulted in tremendous progress in understanding the biology of how this disease develops, increasing screening rates, and decreasing incidence and mortality in those age 50 years and older. The drivers of this movement have been outstanding leadership, innovation, and collaboration. As we move forward to tackle issues such as the increasing incidence of this disease in younger adults, the need to address disparities in care and outcomes, and our shared goal to reach 80% screening rates, it’s important to understand and appreciate the story of our past success in order to advance our future efforts.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    Wolff WI, Shinya H. Polypectomy via the fiberoptic colonoscope: removal of neoplasms beyond reach of the sigmoidoscope. N Engl J Med. 1973;288:329–32.

  2. 2.

    Beahrs O. The medical history of President Ronald Reagan. J Am Coll Surg. 1994;178:86–96.

  3. 3.

    Sorensen RH, Farnsworth GS, Roberts JE, et al. President Reagan’s life saving colectomy and subsequent historical implications. Mil Med. 2014;179:704–7.

  4. 4.

    Thomas H Maugh II. Reagan’s surgery for colon cancer breaks a taboo, brings a floodtide of calls. Los Angeles Times, 1985.

  5. 5.

    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.

  6. 6.

    Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.

  7. 7.

    Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology. 2014;147:502–26.

  8. 8.

    Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.

  9. 9.

    Kewenter J, Brevinge H, Engaras B, et al. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing: results for 68,308 subjects. Scand J Gastroenterol. 1994;29:468–73.

  10. 10.

    Mandel JS, Bond JH, Church TR, et al. Reducing mortal colorectal cancer screen fecal occult blood. N Engl J Med. 1993;328:1365–7.

  11. 11.

    Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet . 1996;348:1467–71.

  12. 12.

    Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American college of physicians. Ann Intern Med. 1997;126:811–22.

  13. 13.

    Shaukat A, Mongin Sj, Geisser MS. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369:1106–14.

  14. 14.

    Collins J, Lieberman D, Durbin T, et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81–85.

  15. 15.

    Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–81.

  16. 16.

    Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–96.

  17. 17.

    Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594–642.

  18. 18.

    Virginia's Legislative Information System. Code of Virginia, 38. 2-3418.7:1: Coverage for colorectal cancer screening. https://law.lis.virginia.gov/vacode/title38.2/chapter34/section38.2-3418.7:1. April 23, 2018.

  19. 19.

    Cram P, Fendrick AM, Inadomi J, et al. The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med. 2003;163:1601–5.

  20. 20.

    Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology . 1997;112:24–28.

  21. 21.

    Bjorkman DJ, Popp JW Jr. Measuring the quality of endoscopy. Am J Gastroenterol. 2006;101:864–5.

  22. 22.

    Cotton PB, Barkun A, Ginsberg G, et al. Diagnostic endoscopy: 2020 vision. Gastrointest Endosc. 2006;64:395–8.

  23. 23.

    GI Quality Improvement Consortium. http://giquic.gi.org/what-is-giquic.asp. April 23, 2018.

  24. 24.

    Pike IM, Eisen GM, Greenwald DA, et al. Increasing adenoma detection rate over time in a national benchmarking registry. Oral presentation, Digestive Diseases Week annual conference. 2017.

  25. 25.

    Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362:1795–803.

  26. 26.

    Kaminski MF, Wieszczy P, Rupinski M, et al. Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death. Gastroenterology. 2017;153:98–105.

  27. 27.

    National Colorectal Cancer Roundtable. 80% by 2018 campaign. http://nccrt.org/what-we-do/80-percent-by-2018/. April 23, 2018.

  28. 28.

    White A, Thompson TD, White MC, et al. Cancer screening test use—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:201–6.

  29. 29.

    Joseph DA, King JB, Richards TB, et al. Use of colorectal cancer screening tests by state. Prev Chronic Dis. 2018;15:170535.

  30. 30.

    Siegel R, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.

  31. 31.

    Williams R, White P, Nieto J, et al. Committee on minority affairs and cultural diversity, american college of gastroenterology. Colorectal cancer in African Americans: an update. Clin Transl Gastroenterol. 2016;7:e185.

  32. 32.

    Ashktorab H, Vimenay K, Brim H, et al. Colorectal cancer in young African Americans: is it time to revisit guidelines and prevention? Dig Dis Sci. 2016;61:3026–30.

  33. 33.

    Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153:307–23.

  34. 34.

    Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109:djw322.

  35. 35.

    Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018.

  36. 36.

    Crockett SD, Snover DC, Ahnen DJ, et al. Sessile serrated adenomas: an evidence-based guide to management. Clin Gastroenterol Hepatol. 2015;13:11–26.

  37. 37.

    IJspeert JE, Tutein Nolthenius CJ, Kuipers EJ, et al. CT-colonography vs. colonoscopy for detection of high-risk sessile serrated polyps. Am J Gastroenterol. 2016;111:516–22.

  38. 38.

    Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.

  39. 39.

    Gralnek IM, Siersema PD, Halpern Z, et al. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. Lancet Oncol. 2014;15:353–60.

  40. 40.

    Leufkens AM, DeMarco DC, Rastogi A, et al. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc. 2011;73:480–9.

  41. 41.

    Triantafyllou K, Polymeros D, Apostolopoulos P, et al. Endocuff-assisted colonoscopy is associated with a lower adenoma miss rate: a multicenter randomized tandem study. Endoscopy. 2017;49:1051–60.

  42. 42.

    Dik VK, Gralnek IM, Segol O, et al. Multicenter, randomized, tandem evaluation of EndoRings colonoscopy—results of the CLEVER study. Endoscopy. 2015;47:1151–8.

  43. 43.

    Halpern Z, Gross SA, Gralnek IM, et al. Comparison of adenoma detection and miss rates between a novel balloon colonoscope and standard colonoscopy: a randomized tandem study. Endoscopy. 2015;47:238–44.

  44. 44.

    Brand EC, Dik VK, Van Oijen MGH, et al. Missed adenomas with behind-folds visualizing colonoscopy technologies compared with standard colonoscopy: a pooled analysis of 3 randomized back-to-back tandem colonoscopy studies. Gastrointest Endosc. 2017;86:376–85.

  45. 45.

    Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.

  46. 46.

    Johnson DA, Barclay RL, Mergener K, et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS ONE. 2014;9:e98238.

  47. 47.

    Sonoda H, Kohnoe S, Yamazato T, et al. Colorectal cancer screening with odour material by canine scent detection. Gut. 2011;60:814–9.

  48. 48.

    Nakhleh MK, Amal H, Jeries R, et al. Diagnosis and classification of 17 diseases from 1404 subjects via pattern analysis of exhaled molecules. ACS Nano. 2017;11:112–25.

  49. 49.

    Hakim M, Broza YY, Barash O, et al. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev. 2012;112:5949–66.

  50. 50.

    Peng G, Hakim M, Broza YY, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103:542–51.

  51. 51.

    Peng G, Tisch U, Adams O, et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol. 2009;4:669–73.

  52. 52.

    Amal H, Leja M, Funka K, et al. Breath testing as potential colorectal cancer screening tool. Int J Cancer. 2016;138:229–36.

  53. 53.

    de Meij T, Larbi I, van der Schee MP, et al. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by faecal volatile markers; proof of principle study. Int J Cancer. 2013;134:1132–8.

  54. 54.

    Altamore DF, Di Lena M, Porcelli F. Exhaled volatile organic compounds detect patients with colon cancer. Br J Surg. 2013;100:144–50.

Download references

Author information

Affiliations

  1. Department of Medicine, Division of Gastroenterology and Hepatology, NYU Langone Health, New York, NY, USA

    • Mark B. Pochapin MD, FACG

Authors

  1. Search for Mark B. Pochapin MD, FACG in:

CONFLICTS OF INTEREST

Guarantor of the article: Mark B. Pochapin, MD, FACG

Specific author contributions: Mark B. Pochapin, MD, FACG

Financial support: None

Potential competing interests: Mark B. Pochapin, MD, FACG, is on the Board of AcuamarkDx, a company that is in the process of making a blood-based test for colon cancer detection.

Corresponding author

Correspondence to Mark B. Pochapin MD, FACG.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41395-018-0187-4